DK168691B1 - Fast farmaceutisk præparat indeholdende nifedipin eller derivater deraf og fremgangsmåde til fremstilling af præparatet - Google Patents

Fast farmaceutisk præparat indeholdende nifedipin eller derivater deraf og fremgangsmåde til fremstilling af præparatet Download PDF

Info

Publication number
DK168691B1
DK168691B1 DK481186A DK481186A DK168691B1 DK 168691 B1 DK168691 B1 DK 168691B1 DK 481186 A DK481186 A DK 481186A DK 481186 A DK481186 A DK 481186A DK 168691 B1 DK168691 B1 DK 168691B1
Authority
DK
Denmark
Prior art keywords
active substance
polyethylene glycol
solution
nifedipine
pharmaceutical composition
Prior art date
Application number
DK481186A
Other languages
Danish (da)
English (en)
Other versions
DK481186D0 (da
DK481186A (da
Inventor
Massimo Calanchi
Piergiorgio Rossi
Original Assignee
Eurand Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand Int filed Critical Eurand Int
Publication of DK481186D0 publication Critical patent/DK481186D0/da
Publication of DK481186A publication Critical patent/DK481186A/da
Application granted granted Critical
Publication of DK168691B1 publication Critical patent/DK168691B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Heat Treatment Of Sheet Steel (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
DK481186A 1985-10-15 1986-10-08 Fast farmaceutisk præparat indeholdende nifedipin eller derivater deraf og fremgangsmåde til fremstilling af præparatet DK168691B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2249485 1985-10-15
IT22494/85A IT1187751B (it) 1985-10-15 1985-10-15 Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute

Publications (3)

Publication Number Publication Date
DK481186D0 DK481186D0 (da) 1986-10-08
DK481186A DK481186A (da) 1987-04-16
DK168691B1 true DK168691B1 (da) 1994-05-24

Family

ID=11197023

Family Applications (1)

Application Number Title Priority Date Filing Date
DK481186A DK168691B1 (da) 1985-10-15 1986-10-08 Fast farmaceutisk præparat indeholdende nifedipin eller derivater deraf og fremgangsmåde til fremstilling af præparatet

Country Status (18)

Country Link
US (1) US4880623A (de)
EP (1) EP0220760B1 (de)
JP (1) JPH0811731B2 (de)
KR (1) KR940006320B1 (de)
AT (1) ATE66367T1 (de)
AU (1) AU590622B2 (de)
CA (1) CA1280976C (de)
DE (1) DE3680989D1 (de)
DK (1) DK168691B1 (de)
ES (1) ES2040209T3 (de)
FI (1) FI87424C (de)
GR (1) GR3003150T3 (de)
HK (1) HK12595A (de)
IT (1) IT1187751B (de)
NO (1) NO172168C (de)
NZ (1) NZ217841A (de)
PT (1) PT83522B (de)
ZA (1) ZA867767B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US5215752A (en) * 1988-03-17 1993-06-01 Vectorpharma International S.P.A. Pharmaceutical tablets and capsule granulates of scleroglucan and active substance
US5028433A (en) * 1988-11-30 1991-07-02 Banyu Pharmaceutical Co., Ltd. Readily absorbable drug formulation of NB-818
GB8903328D0 (en) * 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
GB9025251D0 (en) * 1990-11-20 1991-01-02 Solomon Montague C Nifedipine dosage forms
US5145859A (en) * 1991-03-20 1992-09-08 Case Western Reserve University Methods of treating interstitial cystitis and urethral syndrome
US5271944A (en) * 1991-04-05 1993-12-21 Biofor, Ltd. Pharmacologically enhanced formulations
US5302397A (en) * 1991-11-19 1994-04-12 Amsden Brian G Polymer-based drug delivery system
DK0557244T3 (da) * 1992-02-17 1996-04-01 Siegfried Ag Pharma Dosisformer med forlænget afgivelse af aktivt stof
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
WO1994005262A1 (en) * 1992-09-10 1994-03-17 F.H. Faulding & Co. Limited Sustained release matrix composition
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5543099A (en) * 1994-09-29 1996-08-06 Hallmark Pharmaceutical, Inc. Process to manufacture micronized nifedipine granules for sustained release medicaments
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
MX9801835A (es) 1996-07-08 1998-08-30 Mendell Co Inc Edward Matriz de liberacion sostenida para medicamentos insolubles de dosis altas.
IT1284604B1 (it) * 1996-09-27 1998-05-21 Roberto Valducci Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6485748B1 (en) 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
CA2352211C (en) * 1999-09-30 2009-03-24 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
SK8562002A3 (en) 1999-12-23 2003-10-07 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
IL134701A0 (en) 2000-02-23 2001-04-30 J P M E D Ltd Homogeneous solid matrix containing vegetable proteins
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
EP1401399A2 (de) * 2001-06-22 2004-03-31 Pfizer Products Inc. Pharmzeutische zubereitungen enthaltend anlagerungsprodukte aus polymer und wirkstoff
EP1269994A3 (de) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
DE10142417A1 (de) * 2001-08-31 2003-03-20 Molecular And Clinical Drug Re Arzneimittel
DE10142416A1 (de) * 2001-08-31 2003-03-20 Molecular And Clinical Drug Re Verfahren zur Herstellung von Lösungen
AU2002334987A1 (en) * 2001-10-15 2003-04-28 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
JP2006518754A (ja) * 2003-02-24 2006-08-17 マリンクロッド・インコーポレイテッド ベンズヒドリルチオアセトアミドの改良製法
ES2233227T1 (es) * 2003-03-26 2005-06-16 Teva Pharmaceutical Industries Ltd. Procedimiento para la preparacion de ingredientes farmaceuticos activos con un area superficial especifica.
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
ES2462240T3 (es) * 2006-02-28 2014-05-22 Dart Neuroscience (Cayman) Ltd Piperazinas terapéuticas como inhibidores de PDE4
US20080181966A1 (en) * 2006-10-18 2008-07-31 Cephalon, Inc. Modafinil pharmaceutical compositions
CN102014918A (zh) * 2007-04-20 2011-04-13 太阳医药工业有限公司 由微量沉淀产生的药学组合物
RU2629843C1 (ru) * 2016-05-24 2017-09-04 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Способ получения мази нифедипина (варианты)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO98434A (de) * 1959-04-30
US3920809A (en) * 1973-11-05 1975-11-18 Lilly Co Eli Dibenzo(b,d)pyranone dispersions
US3988439A (en) * 1973-11-05 1976-10-26 Eli Lilly And Company Dibenzo[b,d]pyranone dispersions
DE2400819C2 (de) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
EP0001247A1 (de) * 1977-09-14 1979-04-04 Kanebo, Ltd. Nifedipine enthaltendes Arzneipräparat und Verfahren zu seiner Herstellung.
JPS55129221A (en) * 1979-03-29 1980-10-06 Kaken Pharmaceut Co Ltd Preparation of oral preparation containing hardly soluble medicine
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4311694A (en) * 1979-12-31 1982-01-19 American Cyanamid Company Amorphous coprecipitates of 4-(monoalkylamino) benzoic acid and derivatives and certain water-soluble materials
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
JPS58116414A (ja) * 1981-12-23 1983-07-11 Yamanouchi Pharmaceut Co Ltd ニカルジピン持続性製剤用球形顆粒およびその製造法
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung
HU198844B (en) * 1984-06-14 1989-12-28 Sandoz Ag Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient
IT1178511B (it) * 1984-09-14 1987-09-09 Pharmatec Spa Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
ATE66367T1 (de) 1991-09-15
AU590622B2 (en) 1989-11-09
KR870003779A (ko) 1987-05-04
EP0220760B1 (de) 1991-08-21
IT1187751B (it) 1987-12-23
PT83522A (en) 1986-11-01
DK481186D0 (da) 1986-10-08
FI87424C (fi) 1993-01-11
NO172168B (no) 1993-03-08
FI864151A0 (fi) 1986-10-14
JPH0811731B2 (ja) 1996-02-07
NZ217841A (en) 1990-01-29
PT83522B (pt) 1988-11-30
FI87424B (fi) 1992-09-30
ES2040209T3 (es) 1993-10-16
KR940006320B1 (ko) 1994-07-16
NO864060D0 (no) 1986-10-13
JPS62167727A (ja) 1987-07-24
CA1280976C (en) 1991-03-05
EP0220760A3 (en) 1987-09-23
EP0220760A2 (de) 1987-05-06
US4880623A (en) 1989-11-14
AU6383286A (en) 1987-04-16
DK481186A (da) 1987-04-16
FI864151A (fi) 1987-04-16
NO864060L (no) 1987-04-21
GR3003150T3 (en) 1993-02-17
ZA867767B (en) 1987-06-24
IT8522494A0 (it) 1985-10-15
HK12595A (en) 1995-02-03
DE3680989D1 (de) 1991-09-26
NO172168C (no) 1993-06-16

Similar Documents

Publication Publication Date Title
DK168691B1 (da) Fast farmaceutisk præparat indeholdende nifedipin eller derivater deraf og fremgangsmåde til fremstilling af præparatet
US20230226063A1 (en) Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI673051B (zh) 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
KR101352130B1 (ko) 디클로페낙 제제 및 이용 방법
JP5278708B2 (ja) ナテグリニド含有親水性医薬製剤
JP2010525082A (ja) 固体投与形
PT2050445E (pt) Composição farmacêutica de fenofibrato apresentando uma biodisponibilidade elevada e processo para a sua preparação
KR20030042027A (ko) 나테글리니드 함유 제제
US10894049B2 (en) Pharmaceutical formulation of palbociclib and a preparation method thereof
JP2003516341A (ja) 治療薬
US20110086070A1 (en) Orally disintegrating compositions of rhein or diacerein
US20090155359A1 (en) Granulated particles, tablets and method for producing granulated particles
KR20050039732A (ko) 이부프로펜 결정의 형성 방법
WO2009084041A2 (en) Pharmaceutical compositions of dexibuprofen
WO2016139683A2 (en) Pharmaceutical compositions of lurasidone and process for preparing the same
BRPI0619934A2 (pt) composição farmacêutica de liberação prolongada, processo para a preparação de uma composição, uso de uma composição, e, uso de uma composição
JP2000095682A (ja) 難溶性ＮＳＡＩＤｓ含有固形製剤
WO2021096444A1 (en) Pharmaceutical compositions comprising ticagrelor
WO2000004896A1 (fr) Preparation solides contenant des ains aisement solubles
RU2669920C2 (ru) Фармацевтическая композиция с контролируемым высвобождением, основанная на прионовой кислоте
Sharma et al. Taste masking of promethazine hydrochloride using eudragit E100 via solid dispersion technique to develop fast disintegrating tablets
US8852635B2 (en) Pharmaceutical compositions of fenofibrate
WO2019030773A1 (en) DICLOFENAC COMPOSITIONS WITH LOW DOSE
JPH06500104A (ja) ロペラミド化合物の固体経口剤形を処方するための方法
Tandale et al. The Liquid Technique: A Novel Approach to Improve the Solubility and Bioavailability of Insoluble Drugs